MS药物-话题@MedSci

#MS药物#

7篇内容 | 535人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2062737, encodeId=aeb02062e3753, content=<a href='/topic/show?id=ea19123010c' target=_blank style='color:#2F92EE;'>#MS药物#</a>, objectTitle=EMA确认AbbVie的MS药物Zinbryta的风险超过益处, objectType=article, longId=138663, objectId=4ce31386639e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ce31386639e, replyNumber=0, likeNumber=34, createdTime=2018-09-17, rootId=0, userName=zxl729, userId=5eee468, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ce31386639e, moduleTitle=EMA确认AbbVie的MS药物Zinbryta的风险超过益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ce31386639e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2062735, encodeId=27f52062e35bc, content=<a href='/topic/show?id=ea19123010c' target=_blank style='color:#2F92EE;'>#MS药物#</a>, objectTitle=Alkermes治疗MS药物进入临床一期研究, objectType=article, longId=38059, objectId=0448380598b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0448380598b, replyNumber=0, likeNumber=29, createdTime=2014-12-12, rootId=0, userName=zxl729, userId=5eee468, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0448380598b, moduleTitle=Alkermes治疗MS药物进入临床一期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0448380598b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2062734, encodeId=1a642062e3446, content=<a href='/topic/show?id=ea19123010c' target=_blank style='color:#2F92EE;'>#MS药物#</a>, objectTitle=强生旗下TB药物Sirturo获欧盟支持梯瓦制药旗下MS药物Laquinimod被推迟, objectType=article, longId=28550, objectId=417d2855055, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=417d2855055, replyNumber=0, likeNumber=23, createdTime=2014-04-29, rootId=0, userName=zxl729, userId=5eee468, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=417d2855055, moduleTitle=强生旗下TB药物Sirturo获欧盟支持梯瓦制药旗下MS药物Laquinimod被推迟, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=417d2855055)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2062736, encodeId=90772062e362d, content=<a href='/topic/show?id=ea19123010c' target=_blank style='color:#2F92EE;'>#MS药物#</a>, objectTitle=百健艾迪重磅MS药物Plegridy获FDA批准, objectType=article, longId=39214, objectId=3def3921438, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3def3921438, replyNumber=0, likeNumber=40, createdTime=2015-03-10, rootId=0, userName=zxl729, userId=5eee468, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3def3921438, moduleTitle=百健艾迪重磅MS药物Plegridy获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3def3921438)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2062732, encodeId=1bb12062e325b, content=<a href='/topic/show?id=ea19123010c' target=_blank style='color:#2F92EE;'>#MS药物#</a>, objectTitle=FDA审查人员对赛诺菲旗下MS药物阿仑单抗安全性表示担忧, objectType=article, longId=26493, objectId=4f6c2649325, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f6c2649325, replyNumber=0, likeNumber=35, createdTime=2014-07-01, rootId=0, userName=zxl729, userId=5eee468, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f6c2649325, moduleTitle=FDA审查人员对赛诺菲旗下MS药物阿仑单抗安全性表示担忧, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f6c2649325)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2062733, encodeId=724c2062e338c, content=<a href='/topic/show?id=ea19123010c' target=_blank style='color:#2F92EE;'>#MS药物#</a>, objectTitle=FDA委员会：安全性问题不妨碍赛诺菲MS药物Lemtrada的获批, objectType=article, longId=26815, objectId=d85c2681508, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d85c2681508, replyNumber=0, likeNumber=29, createdTime=2014-06-17, rootId=0, userName=zxl729, userId=5eee468, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d85c2681508, moduleTitle=FDA委员会：安全性问题不妨碍赛诺菲MS药物Lemtrada的获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d85c2681508)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2062731, encodeId=da532062e3178, content=<a href='/topic/show?id=ea19123010c' target=_blank style='color:#2F92EE;'>#MS药物#</a>, objectTitle=FDA:警惕MS药物的癫痫发作风险, objectType=article, longId=8302, objectId=32648302fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32648302fc, replyNumber=0, likeNumber=26, createdTime=2013-02-06, rootId=0, userName=zxl729, userId=5eee468, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32648302fc, moduleTitle=FDA:警惕MS药物的癫痫发作风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32648302fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

MS药物

2020-05-29

zxl729 (审核中...)

前往app查看评论内容

#MS药物#

EMA确认AbbVie的MS药物Zinbryta的风险超过益处

2018-09-17

zxl729 (审核中...)

前往app查看评论内容

#MS药物#

Alkermes治疗MS药物进入临床一期研究

2014-12-12

zxl729 (审核中...)

前往app查看评论内容

#MS药物#

强生旗下TB药物Sirturo获欧盟支持梯瓦制药旗下MS药物Laquinimod被推迟

2014-04-29

zxl729 (审核中...)

前往app查看评论内容

#MS药物#

百健艾迪重磅MS药物Plegridy获FDA批准

2015-03-10

zxl729 (审核中...)

前往app查看评论内容

#MS药物#

FDA审查人员对赛诺菲旗下MS药物阿仑单抗安全性表示担忧

2014-07-01

zxl729 (审核中...)

前往app查看评论内容

#MS药物#

FDA委员会：安全性问题不妨碍赛诺菲MS药物Lemtrada的获批

2014-06-17

zxl729 (审核中...)

前往app查看评论内容

#MS药物#

FDA:警惕MS药物的癫痫发作风险

2013-02-06

科室
- - 订阅+
  - 更多科室
工具
服务